Rivastigmine: A pharmacoeconomic review of its use in Alzheimer's disease

PharmacoEconomics

Volumn 19, Issue 3, 2001, Pages 303-318

  Lamb, H M ^a   Goa, K L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE; TACRINE;

AGITATION; ALZHEIMER DISEASE; ASTHENIA; BEHAVIOR DISORDER; CAREGIVER; COGNITIVE DEFECT; COST CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INSOMNIA; INSTITUTIONALIZATION; LIVER TOXICITY; PRIORITY JOURNAL; REVIEW; SHORT TERM MEMORY; VERTIGO;

EID: 0035085948     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119030-00008     Document Type: Review

References (78)

1. Epidemiology of dementias
2. Treatment of Alzheimer's disease
3. The incidence of dementia: A meta-analysis
4. Economic considerations in Alzheimer's disease
5. The social consequences for families with Alzheimer's disease patients: Potential impact of new drug treatment
6. Informal care of community-dwelling patients with Alzheimer's disease: Focus on the family caregiver
7. The personal and social consequences of Alzheimer disease
8. Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease
9. Severe dementia: A common condition entailing high costs at individual and societal levels
10. An economic perspective on Alzheimer's disease
11. The cholinergic hypothesis of Alzheimer's disease: A review of progress
12. Assessing the societal impact of acetylcholinesterase inhibitor therapies
13. EUROCARE: A cross-national study of co-resident spouse carers for people with Alzheimer's disease: I-Factors associated with carer burden
14. The economic burden of Alzheimer's disease care
15. Economic impact of Alzheimer's disease in the United Kingdom: Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease
16. The cost of institutional care in Alzheimer's disease: Nursing home and hospital use in a prospective cohort
17. Predictors of time to institutionalization of patients with Alzheimer's disease: The CERAD experience, part XVII
18. Time until institutionalization and death in patients with dementia: Role of caregiver training and risk factors
19. Early-onset Alzheimer's disease: Clinical predictors of institutionalization and death
20. Longitudinal study of death and institutionalization in patients with primary degenerative dementia
21. Predictors of nursing home placement in patients with Alzheimer's disease
22. Predictors of institutionalization among caregivers of patients with Alzheimer's disease
23. The economic consequences of Alzheimer's disease in the context of new drug developments
24. Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines
25. Economic research on Alzheimer disease: A review of the literature
26. Alzheimer's disease care: Costs and potential savings
27. Relation between severity of Alzheimer's disease and costs of caring
28. First International Pharmacoeconomic Conference on Alzheimer's Disease: Report and summary
29. The costs and social burdens of Alzheimer disease: What can and should be done?
30. Economic considerations in the treatment and management of Alzheimer's disease
31. The US economic and social costs of Alzheimer's disease revisited
32. Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications
33. Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly
34. Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology
35. Cholinesterase inhibitors: A new class of psychotropic compounds
36. Cholinesterase inhibitors: A therapeutic strategy for Alzheimer disease
37. Pharmacology and clinical efficacy of cholinesterase inhibitors
38. A 5-month, randomized, placebo-controlled trial of galantamine in AD
39. Selectivity of cholinesterase inhibition: Clinical implications for the treatment of Alzheimer's disease
40. Galantamine: A review of its use in Alzheimer's disease
41. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised control trial
42. Rivastigmine provides behavioral benefits to Alzheimer's disease patients residing in a nursing home: Findings from a 26-week trial
43. Behavioral benefits in Alzheimer's disease patients residing in a nursing home following 52 weeks of rivastigmine treatment
44. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
45. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
46. Dose-response effect of rivastigmine in the treatment of Alzheimer's disease
47. Long-term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease: Results following two years of treatment
48. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease
49. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study
50. Spontaneous rupture of oesophagus (Boerhaave's syndrome) related to rivastigmine
51. Effectiveness of rivastigmine in Alzheimer's disease reply
52. Effectiveness of rivastigmine in Alzheimer's disease: Improvements in functional ability remain unestablished
53. Effectiveness of rivastigmine in Alzheimer's disease: Participation in trials should be based on clinical uncertainty, not enforcement: Authors' reply
54. Donepezil: Pharmacoeconomic implications of therapy
55. Drug treatments for Alzheimer's disease: Shifting the burden of care
56. Estimating long term cost savings from treatment of Alzheimer's disease: A modelling approach
57. The effect of rivastigmine on the direct and indirect costs of Alzheimer's disease
58. Cognitive function and the costs of Alzheimer disease: An exploratory study
59. Alzheimer's disease: The burden of the illness in England
60. Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine
61. Potential savings in the cost of caring for Alzheimer's disease: Patient treatment with rivastigmine
62. Cost savings from decreased utilization of antipsychotic drugs associated with rivastigmine use in long-term care facilities
63. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality
64. An economic evaluation of donepezil in the treatment of Alzheimer's disease
65. Cholinesterase inhibitors in Alzheimer's disease: Are they worth the cost?
66. The epidemic of Alzheimer's disease: How can we manage the costs?
67. Aricept better tolerated than Exelon, claim Eisai/Pfizer
68. The cost of Alzheimer's disease: Will drug treatment ease the burden?
69. Impact of rivastigmine on costs and time spent caring for Alzheimer's disease patients
70. Clinical predictors of the indirect costs of Alzheimer disease
71. Clinical predictors of the indirect costs of Alzheimer disease: Reply
72. A multidisciplinary team approach to managing Alzheimer's disease
73. A family intervention to delay nursing home placement of patients with Alzheimer disease: A randomized controlled trial
74. Service use and cost outcomes for persons with Alzheimer disease
75. Factors affecting the utilization of homecare supports by caregiving relatives of Alzheimer patients